No change of serum levels of leptin and adiponectin during anti‐tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis

Παρόμοια τεκμήρια

• Anti-tumour necrosis factor antibody treatment does not change serum levels of cortisol binding globulin in patients with rheumatoid arthritis but it increases androstenedione relative to cortisol
  ανά: Straub, R, κ.ά.
  Έκδοση: (2005)
• Clinical response to adalimumab: relationship to anti‐adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
  ανά: Bartelds, Geertje M, κ.ά.
  Έκδοση: (2007)
• Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
  ανά: Capsoni, Franco, κ.ά.
  Έκδοση: (2005)
• A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis
  ανά: Miceli-Richard, Corinne, κ.ά.
  Έκδοση: (2008)
• Early rheumatoid arthritis
  ανά: P. Sarzi-Puttini, κ.ά.
  Έκδοση: (2011-09-01)